NEW YORK (GenomeWeb) – Enzo Biochem said on Monday that its revenues for its fiscal third quarter were up 6 percent year over year.

For the three months ended April 30, the company reported total revenues of $24 million, up from $22.6 million in the year-ago quarter. Enzo's Clinical Labs segment revenues rose to 9 percent $14.5 million from $13.4 million, while Life Science product revenues increased 5 percent to $8.7 million from $8.3 million. Royalty and licensing fee income slid to $729,000 from $949,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.